Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.435
-0.125 (-4.88%)
Oct 10, 2025, 11:19 AM EDT - Market open
Protalix BioTherapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Protalix BioTherapeutics stock has a target of 15, which predicts a 516.02% increase from the current stock price of 2.44.
Price Target: $15 (+516.02%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 3, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Protalix BioTherapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +516.02% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +310.68% | Nov 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +310.68% | Oct 31, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +187.47% | May 3, 2021 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $11 | Strong Buy | Maintains | $3 → $11 | +351.75% | Jun 8, 2020 |
Financial Forecast
Revenue This Year
61.16M
from 53.40M
Increased by 14.53%
Revenue Next Year
107.50M
from 61.16M
Increased by 75.77%
EPS This Year
0.13
from 0.04
Increased by 258.22%
EPS Next Year
0.55
from 0.13
Increased by 319.23%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 65.0M | 125.4M | |
| Avg | 61.2M | 107.5M | |
| Low | 58.0M | 91.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 21.7% | 105.1% | |
| Avg | 14.5% | 75.8% | |
| Low | 8.6% | 49.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.22 | 0.78 | |
| Avg | 0.13 | 0.55 | |
| Low | 0.05 | 0.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 501.6% | 491.8% | |
| Avg | 258.2% | 319.2% | |
| Low | 33.7% | 161.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.